Roadshow
ACTOnco®+ analyzes
ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies.
ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.

- Established 2014
- Company ACT Genomics
- Telephone +886-2-2795-3660
- Email tinachen@actgenomics.com
- Address 3F, No. 345, Xinhu 2nd Rd., Neihu Dist., Taipei City 114065, Taiwan (R.O.C.)
<p>ACT Genomics is an award-winning cancer solution provider founded in 2014 by a small group of scientists from academia. With our name, ACT Genomics, reflecting our passion to “turn genomics into action”, we set out to apply academic theories in clinical practice and truly make personalized cancer care accessible to all.</p> <p> </p> <p>Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.</p>